Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism
Authors
Keywords
PCSK9, Low-density lipoprotein receptor, Glucagon-like peptide-1, Liraglutide, Type 2 diabetes mellitus
Journal
Cardiovascular Diabetology
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-19
DOI
10.1186/s12933-018-0689-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells
- (2017) Gabriele Catyana Krause et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
- (2017) Christian Baumeier et al. Molecular Metabolism
- Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
- (2016) Yu Wang et al. Cardiovascular Diabetology
- Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
- (2016) Josefa Girona et al. Cardiovascular Diabetology
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Effect of Leptin Replacement on PCSK9 inob/obMice and Female Lipodystrophic Patients
- (2016) Amy E. Levenson et al. ENDOCRINOLOGY
- No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
- (2016) Helen M. Colhoun et al. EUROPEAN HEART JOURNAL
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells
- (2016) Chuan-Jue Cui et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
- (2016) Ying Du et al. Journal of Translational Medicine
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9Significance
- (2015) Ji Miao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis
- (2015) S. Farr et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels
- (2015) Bin Dong et al. ATHEROSCLEROSIS
- Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism
- (2015) Changting Xiao et al. DIABETES
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Positive correlation of plasma PCSK9 levels with HbA1cin patients with type 2 diabetes
- (2015) Sheng-Hua Yang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice
- (2015) Sander Kooijman et al. DIABETOLOGIA
- Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway
- (2015) Na Ao et al. HEPATOLOGY RESEARCH
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes
- (2015) Tomohiko Kimura et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism
- (2014) Bin Dong et al. ATHEROSCLEROSIS
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- The effect of insulin on circulating PCSK9 in postmenopausal obese women
- (2014) Zuhier Awan et al. CLINICAL BIOCHEMISTRY
- GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
- (2014) Jennifer M. Trujillo et al. PHARMACOTHERAPY
- GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance
- (2014) Jennifer Taher et al. Molecular Metabolism
- Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype
- (2013) Zuhier Awan et al. CANADIAN JOURNAL OF CARDIOLOGY
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
- (2012) Yuya Fujishima et al. Cardiovascular Diabetology
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
- (2012) Edwin T. Parlevliet et al. PLoS One
- Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study
- (2011) M.C.G.J. Brouwers et al. ATHEROSCLEROSIS
- The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes
- (2011) M. Shimoda et al. DIABETOLOGIA
- Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
- (2010) Qin Cui et al. ATHEROSCLEROSIS
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- In vitro toxicity evaluation of graphene oxide on A549 cells
- (2010) Yanli Chang et al. TOXICOLOGY LETTERS
- PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
- (2009) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
- (2009) A. Baass et al. CLINICAL CHEMISTRY
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
- (2009) Majambu Mbikay et al. FEBS LETTERS
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Nanosized zinc oxide particles induce neural stem cell apoptosis
- (2009) Xiaoyong Deng et al. NANOTECHNOLOGY
- LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
- (2009) Noam Zelcer et al. SCIENCE
- Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors
- (2008) Lena Persson et al. ENDOCRINOLOGY
- Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms
- (2008) Elisabeth B. Rüttimann et al. ENDOCRINOLOGY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now